Rendiatech Overview
Rendiatech is a medical device company dedicated to real-time renal diagnostics. The company’s first commercially available product, Clarity RMS, is a critical care monitoring system that has been clinically proven to facilitate early detection of changes in renal function and acute kidney injury (AKI) risk, in addition to treatment monitoring. Clarity RMS provides continuous, automatic monitoring of urine flow, enabling better patient care and ICU economics. It also provides additional real-time parameters and expanded diagnostic capabilities to further improve critical care management in the ICU and perioperative setting. The Clarity RMS system has FDA clearance as well as CE certification and is installed in tens of general and cardiovascular operating rooms, ICUs, and transplant and COVID-19 units in leading medical centers in the U.S., Europe, and Israel. Future sensor-based products will aim to provide additional diagnostic data about renal and other vital organ function beyond the critical care setting.
Cumulative Funding Raised Over Time ($)
$1.0MJan 2011
$11.0MJan 2018
$15.0MMar 2014
$29.0MNov 2021
Latest News
growth-positive
Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company
Nuwellis, Inc., a medical technology company, announced a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli-based medical device company. This acquisition aims to expand Nuwellis fluid management offerings by incorporating continuous renal health monitoring technologies. Rendiatechs Clarity RMS, an FDA-cleared system, will be added to Nuwellis portfolio, enhancing their ability to provide real-time urine flow monitoring. The acquisition aligns with Nuwellis strategy to improve patient outcomes and accelerate growth. The transaction is expected to close in the fourth quarter of 2025, pending due diligence and board approval. This strategic move is anticipated to strengthen Nuwellis market position and unlock value for stakeholders.
Acquisition
growth-positive
Start-up RenalSense aims to bring renal diagnostics to ICUs worldwide
Israeli MedTech start-up RenalSense has raised $14 million in a Series A funding round led by BlueRed Partners Fund. The company plans to use the funding to achieve global commercialization and installment in medical centers worldwide. RenalSenses flagship product, the Clarity RMS, is a critical care monitoring system that automatically monitors urine flow to enable early detection of changes in renal function and Acute Kidney Injury risk. The company has expanded its global marketing network from Europe, North America and China to include Israel and Taiwan.
InvestmentExpand
growth-positive
RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line
RenalSense has secured $14M in Series A funding to support the global commercialization of its Clarity RMS product, expand clinical validation, and develop next-generation sensor-based products. The funding round was led by BlueRed Partners Fund and included healthcare-focused family offices and existing shareholders. The Clarity RMS is a critical care monitoring system that detects changes in renal function and Acute Kidney Injury risk. It has FDA clearance and CE-certification and is installed in medical centers worldwide. RenalSense plans to extend its product line and expand its reach to Asia. The company has also added new distributors in eastern Europe, Israel, and Taiwan.
InvestmentExpand
growth-positive
RenalSense Announces Distribution Agreement in Mainland China with Gloryway
RenalSense has announced a distribution agreement with Gloryway, a leading distributor in mainland China of medical devices. Gloryway will market and manufacture RenalSenses Clarity RMS critical care monitoring system to hospitals throughout mainland China. The system facilitates early detection of changes in renal function and Acute Kidney Injury (AKI) risk. Clarity RMS is already installed in several intensive care units (ICU) worldwide. RenalSenses CEO hopes to make Clarity RMS a standard of care in China, given the growing need for early detection and treatment monitoring in the Chinese market. The agreement will enhance Gloryways presence in intensive care units and improve the monitoring of critical patients.
Partners
growth-positive
Medline, RenalSense Partner to Offer UO Monitoring System
Medline Industries has signed a commercial distribution partnership with RenalSense for the North American market. The partnership will allow RenalSense to scale its sales and marketing efforts while enhancing Medlines offerings to healthcare workers. RenalSenses Clarity RMS patient monitoring system measures urine flow rates and transmits real-time data to medical staff and electronic medical records. Medline currently offers Foley catheter tray options and the addition of RenalSenses technology will further improve their offerings. The partnership will give RenalSense access to Medlines customer base and marketing organization, while Medline can provide additional value to its customers through real-time urine output monitoring.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $29.83M |
| Last funding | $14M |
| Stage | Acquired |
| Rounds | 5 |
| Investors | 1 |
Team Members
5
Employees: 1-10
Web & Social Links
Locations
HaMarpe Street 3, Jerusalem, Israel
1309 Beacon Street, Brookline, MA 02446, USA
Photos & Videos
4 item(s)
Rendiatech Business
Business models
B2B, B2B2C
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesDiagnostics DevicesMedical MonitorsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
Artificial IntelligenceMachine LearningSensingTags (11)
early-detectionsensorsnephrologymedical-devicesreal-timediagnosticspreventionmonitoringhospitalsmedical-technologiesnon-invasiveGeographic Markets
GlobalEuropeNorth AmericaRendiatech Financials
$29.83M
Total funding
Undisclosed
Capital raised
$14M
Last funding
Acquired
Funding stage
5
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$1.0MJan 2011
$11.0MJan 2018
$15.0MMar 2014
$29.0MNov 2021
Private Equity Funding
A Round
Nov 2021
$14M
BlueRed Partners (Lead)
Seed
Jan 2018
$10M
Seed
Mar 2014
$4M
Pre-Seed
Jan 2011
$1M
Non-Equity Funding
GrantEvent
May 2019
$828K
Israel Innovation Authority
Public Offering / Exit
MNAEvent
Aug 2025
Undisclosed
Rendiatech Lifecycle
Cumulative Funding Raised Over Time
$1.0MJan 2011
$11.0MJan 2018
$15.0MMar 2014
$29.0MNov 2021
All Events
A Round
Nov 2021
$14M
BlueRed Partners (Lead)
Seed
Jan 2018
$10M
Seed
Mar 2014
$4M
Pre-Seed
Jan 2011
$1M
GrantEvent
May 2019
$828K
Israel Innovation Authority
MNAEvent
Aug 2025
Undisclosed
Rendiatech News
14 articles
growth-positive
Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company
Nuwellis, Inc., a medical technology company, announced a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli-based medical device company. This acquisition aims to expand Nuwellis fluid management offerings by incorporating continuous renal health monitoring technologies. Rendiatechs Clarity RMS, an FDA-cleared system, will be added to Nuwellis portfolio, enhancing their ability to provide real-time urine flow monitoring. The acquisition aligns with Nuwellis strategy to improve patient outcomes and accelerate growth. The transaction is expected to close in the fourth quarter of 2025, pending due diligence and board approval. This strategic move is anticipated to strengthen Nuwellis market position and unlock value for stakeholders.
Acquisition
growth-positive
Start-up RenalSense aims to bring renal diagnostics to ICUs worldwide
Israeli MedTech start-up RenalSense has raised $14 million in a Series A funding round led by BlueRed Partners Fund. The company plans to use the funding to achieve global commercialization and installment in medical centers worldwide. RenalSenses flagship product, the Clarity RMS, is a critical care monitoring system that automatically monitors urine flow to enable early detection of changes in renal function and Acute Kidney Injury risk. The company has expanded its global marketing network from Europe, North America and China to include Israel and Taiwan.
InvestmentExpand
growth-positive
RenalSense raises $14M Series A Funding to Bolster Global Commercialization and Expand its Product Line
RenalSense has secured $14M in Series A funding to support the global commercialization of its Clarity RMS product, expand clinical validation, and develop next-generation sensor-based products. The funding round was led by BlueRed Partners Fund and included healthcare-focused family offices and existing shareholders. The Clarity RMS is a critical care monitoring system that detects changes in renal function and Acute Kidney Injury risk. It has FDA clearance and CE-certification and is installed in medical centers worldwide. RenalSense plans to extend its product line and expand its reach to Asia. The company has also added new distributors in eastern Europe, Israel, and Taiwan.
InvestmentExpand
growth-positive
RenalSense Announces Distribution Agreement in Mainland China with Gloryway
RenalSense has announced a distribution agreement with Gloryway, a leading distributor in mainland China of medical devices. Gloryway will market and manufacture RenalSenses Clarity RMS critical care monitoring system to hospitals throughout mainland China. The system facilitates early detection of changes in renal function and Acute Kidney Injury (AKI) risk. Clarity RMS is already installed in several intensive care units (ICU) worldwide. RenalSenses CEO hopes to make Clarity RMS a standard of care in China, given the growing need for early detection and treatment monitoring in the Chinese market. The agreement will enhance Gloryways presence in intensive care units and improve the monitoring of critical patients.
Partners
growth-positive
Medline, RenalSense Partner to Offer UO Monitoring System
Medline Industries has signed a commercial distribution partnership with RenalSense for the North American market. The partnership will allow RenalSense to scale its sales and marketing efforts while enhancing Medlines offerings to healthcare workers. RenalSenses Clarity RMS patient monitoring system measures urine flow rates and transmits real-time data to medical staff and electronic medical records. Medline currently offers Foley catheter tray options and the addition of RenalSenses technology will further improve their offerings. The partnership will give RenalSense access to Medlines customer base and marketing organization, while Medline can provide additional value to its customers through real-time urine output monitoring.
Partners
growth-positive
RenalSense Announces Distribution Agreement in Israel with Medtechnica
RenalSense has announced a distribution agreement with Medtechnica, Israels largest distributor of medical equipment and health services. Medtechnica will market RenalSenses Clarity RMS critical care monitoring system to hospitals throughout Israel. This partnership will enhance critical care in Israel and expand RenalSenses customer base. RenalSense is also in discussions with additional partners for distribution agreements in other key markets.
Partners
growth-positive
Real-Time Urine Flow Rate Measurement: Interview with Christopher Strafaci, VP of Sales and Marketing at RenalSense
CHF Solutions has signed a distribution agreement with RenalSense to sell the ClarityRMS urine flow real-time monitoring system. The system provides healthcare staff with real-time information on urine flow, allowing for the identification of fluid overload and timely treatment. The partnership will help more hospitals in certain US territories gain access to automatic, real-time data monitoring for renal function.
Partners
COVID-19 and Acute Kidney Injury
growth-positive
Novel Coronavirus Presents Unique Challenges for Hospital Staff and Patients in Isolation
RenalSense, a medical device company, offers the Clarity RMS® system for continuous monitoring of urine flow in patients, particularly those with COVID-19. The system provides real-time data and notifications to medical staff, allowing for early detection of Acute Kidney Injury (AKI) risk. The technology reduces the need for manual monitoring and limits staff exposure to infected patients. RenalSense aims to improve patient care and ICU economics with its products. The article does not mention any specific partners, customers, valuation amount, layoffs, or investment amount. The event described in the article is ongoing, as it discusses the impact of the COVID-19 pandemic. My confidence in this answer is 8/10.
Customers
growth-positive
RenalSense starts Delivery of its First Orders of Clarity RMS in Europe - JLM-BioCity
RenalSense has started commercial sales of its Clarity RMS™ system in Europe with its distribution partner Fresenius Medical Care. The Clarity RMS facilitates early detection of changes in renal function and Acute Kidney Injury (AKI) risk. RenalSense obtained CE Mark approval and ISO:13485:2016 certification. The company aims to deliver Clarity RMS to hundreds of medical centers in Europe.
CustomersPartners
growth-positive
RenalSense Obtains CE Mark for its Clarity RMS™ Critical Care System for Real-time Monitoring of Urine Flow
RenalSense has obtained CE Mark approval for its Clarity RMS system for real-time monitoring of urine flow in critical care and peri-operative settings. The approval allows RenalSense to commercialize its technology in the European Union, with Fresenius Medical Care as its distribution partner. The Clarity RMS system facilitates early detection of changes in renal function and Acute Kidney Injury risk. RenalSense is a privately owned medical device company dedicated to real-time renal diagnostics. They have also received ISO:13485:2016 certification for their quality management system.
Partners
growth-positive
Israel Grants $6.9M To 3 Medtech Companies For Innovation
The Israeli Ministry of Economy and Industry and the Israel Innovation Authority are providing over NIS 25 million ($6.9 million) in grants to innovative medical technology companies. The funding is part of an R&D program to support new and innovative medical technologies. The companies that received funding include Enlivex, Cathworks, and RenalSense. Enlivex received NIS 4 million, Cathworks received NIS 3.6 million, and RenalSense received NIS 3 million. The funding aims to maintain Israels position as a global leader in innovation and promote sustainable economic growth.
Investment
growth-positive
RenalSense Conducts Pilot Study at University of Pittsburgh Medical Center
RenalSense is conducting a pilot study with its Clarity RMS critical care monitoring system at the University of Pittsburgh Medical Center (UPMC) to assess its contribution towards improving the nursing workflow in the ICU. The study aims to incorporate real-time urine output monitoring into the nursing workflow and ICU standard of care. RenalSense is a privately owned medical device company dedicated to real-time renal diagnostics. Their first product, Clarity RMS, provides continuous monitoring of urine flow. RenalSenses next generation products will offer additional real-time parameters and expanded diagnostic capabilities.
CustomersPartners
growth-positive
RenalSense Announces Distribution Agreement With Fresenius Medical Care
RenalSense has entered into an agreement with Fresenius Medical Care for the distribution of its Clarity RMS critical care urine monitoring system in Europe, the Middle East, and Africa. Fresenius Medical Care will market RenalSenses products in 85 EMEA countries through its acute care division. This partnership will contribute to the growth of RenalSense by expanding its market reach and increasing sales potential.
Partners
Rendiatech Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 9 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Rendiatech Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 94/100 |
| Missing | homepage, markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 517143046 |
| Crunchbase | renalsense |
| Phone | +97225022562 |
| Creator | Arielle Smolin |
| Creator email | ari.smolin@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2025-08-27T00:00:00.000Z |
| Created | 2014-07-07T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Acquired by Nuwellis on Aug, 2025 |